Bliss GVS Pharma Ltd share price logo

Bliss GVS Pharma Ltd

NSE: BLISSGVS

BSE: 506197

Small Cap

Pharma Sector

₹666.00

-18.95

(-2.77%)

as on

bell
The current prices are delayed by 15 mins, login to check live prices.

Tech Chart

What are INDmoney investors doing with Bliss GVS Pharma shares?

Based on platform-user behaviour - not analyst opinion or company fundamentals.

Search interest on INDmoney

+65%

Searches for Bliss GVS Pharma on INDmoney have increased by 65% over the last 30 days.

Investment activity on INDmoney

+161.54%

Investment activity in Bliss GVS Pharma among INDmoney users has increased by 161.54% over the last 30 days.

Average holding period of indmoney investors

11 days

INDmoney investors hold Bliss GVS Pharma shares for an average of 11 days.

Key Events for Bliss GVS Pharma

Last Dividend Declared

₹1.00 per share, declared on 12/05/2026

View Dividend History

Bliss GVS Pharma Stock Performance

as on September 16, 2026 at 7:44 pm IST

  • Day's Low

    Day's High

    ₹650.75
    ₹676.45
    downward going graph

    2.29%

    Downside

    1.57%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    ₹118.00
    ₹725.90
    downward going graph

    82.28%

    Downside

    8.99%

    Upside

    downward going graph

Bliss GVS Pharma share price movements today

Previous Close
₹684.95
Open
₹666.00
Volume
3.39L
Upper Circuit
₹719.15
Lower Circuit
₹650.75
Day's Low - High
₹650.75 - ₹676.45
52 Week Low - High
₹118.00 - ₹725.90

Bliss GVS Pharma Historical Returns

1 Month Return
+ 31.59 %
3 Month Return
+ 51.57 %
1 Year Return
+ 352.44 %
3 Year Return
+ 641.29 %
5 Year Return
+ 511.02 %

Bliss GVS Pharma Fundamentals

as on September 16, 2026 at 2:14 pm IST

Market Cap

₹7,283.11 Cr

Return on Equity (ROE)

8.75

PE Ratio (TTM)

55.97

Return on capital employed (ROCE)

12.51

Industry PE ratio

51.81

Beta (LTM)

1.21

P/B Ratio

1.97

Dividend Yield

0.46

PEG Ratio

20.35

Quarterly Earnings Growth YOY

15.8

EPS (TTM)

12.74

Book Value

112.76

Bliss GVS Pharma Stock Valuation

as on September 16, 2026 at 2:14 pm IST

Bliss GVS Pharma in the last 5 years

  • Overview

  • Trends

Lowest (7.08x)

August 22, 2019

Industry (51.81x)

September 11, 2026

Today (55.97x)

September 11, 2026

Highest (576.11x)

January 3, 2022

LowHigh

Today’s Price to Earnings Ratio: 55.97x

Bliss GVS Pharma Technical Analysis

Track how Bliss GVS Pharma technical analysis has moved over time to understand its trends.

1 min
5 min
15 min
30 min
1 day
1 week
1 month

Technicals Summary

Bearish

Neutral

Bullish

Bullish

Moving Averages

Bearish

Neutral

Bullish

Bullish

Oscillators

Bearish

Neutral

Bullish

Bullish

Overall

Bearish
Bullish13
Neutral2

Oscillators

Name

Value

Action

MACD level (12,26)
1.06
Bullish
CCI (20)
12.45
Neutral
RSI (14)
59.85
Neutral
Momentum (10)
4
Bullish
ADI (14)
35.03
Bullish
Ultimate Oscillator (7,14,28)
71.25
Bullish

Moving Averages

Name

Value

Action

SMA (20)
665.99
Bullish
EMA (20)
666.12
Bullish
VWMA (20)
666.61
Bullish
SMA (50)
664.24
Bullish
EMA (50)
664.18
Bullish
SMA (200)
661.24
Bullish
EMA (200)
662.59
Bullish
KAMA (200)
663.02
Bullish
DEMA (200)
659.84
Bullish

Bliss GVS Pharma Ltd vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Bliss GVS Pharma with its industry peers.

Company
Analyst View
Market Cap(in ₹ Cr)
5 Year CAGRDebt to Asset Ratio
Net Profit(in ₹ Cr)
Yearly Revenue(in ₹ Cr)
Bliss GVS Pharma Ltd image
Bliss GVS Pharma Ltd
NA7,283.11102.2%0.53134927
Bacil Pharma Ltd image
Bacil Pharma Ltd
NA29.1947.69%0.001NA
Concord Biotech Ltd image
Concord Biotech Ltd
BUY15,409.9711.25%0.502591,054
Beryl Drugs Ltd image
Beryl Drugs Ltd
NA11.7921.54%0.00-121
Natco Pharma Ltd image
Natco Pharma Ltd
HOLD14,671.79-3.06%0.541,3714,078
See all

Bliss GVS Pharma Ltd Quarterly Profit & Loss

Figures in Rupees Crores

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Sales
211.88
200.72
198.13
183.64
217.68
210.42
197.99
207.47
244.4
218.25
256.99
285.58
Other Income
12.6
5.42
5.6
4.12
5.04
15.27
12.07
35.45
8.46
18.46
11.19
9.6
Total Income
224.48
206.14
203.73
187.77
222.72
225.68
210.05
242.92
252.86
236.71
268.18
295.18
Expenses
157.51
157.02
198.98
149.31
176.2
180.63
176.9
166.14
200.92
185.98
212.55
209.18
Operating Profit
54.37
43.7
-0.85
34.33
41.48
29.79
21.09
41.33
43.48
32.27
44.44
76.4
Operating Profit Margin %
25.66%
21.77%
-0.43%
18.69%
19.06%
14.16%
10.65%
19.92%
17.79%
14.79%
17.29%
26.75%
Profit Before Interest, Tax and Depreciation
66.97
49.12
4.75
38.45
46.51
45.05
33.15
76.78
51.94
50.73
55.63
86
Interest
1.45
2.12
1.85
1.53
3.83
1.08
1.68
5.47
3.04
1.49
2.01
0.58
Depreciation
6.39
6.95
6.85
6.85
6.98
7.55
8.04
8.2
8.26
8.35
8.67
9.94
Profit Before Tax
59.13
40.05
-3.95
30.07
35.7
36.42
23.43
63.11
40.64
40.89
44.95
75.48
Tax Paid
16.08
10.97
0.96
7.96
10.01
10.62
6.79
18.74
12.04
16.12
7.95
24.11
Profit After Tax
43.04
29.07
-4.91
22.11
25.69
25.8
16.65
44.36
28.59
24.78
37
51.37
Total Net profit including share of profit / Loss from associate company
43.04
29.07
-4.91
22.11
25.69
25.8
16.65
44.36
28.59
24.78
37
51.37
EPS
4.06
2.64
-0.88
1.97
2.31
2.27
1.47
4.08
2.58
2.2
3.37
4.73
Actual EPS
4.06
2.64
-0.88
1.97
2.31
2.27
1.47
4.08
2.58
2.2
3.37
4.73
Adjusted EPS
4.06
2.64
-0.88
1.97
2.31
2.27
1.47
4.08
2.58
2.2
3.37
4.73
Diluted EPS
3.98
2.6
-0.86
1.93
2.29
2.27
1.46
4.04
2.54
2.14
3.28
4.65

Bliss GVS Pharma Ltd Annual Profit & Loss

Figures in Rupees Crores

Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
Sales
814.64
898.57
689.31
577.21
747.45
751.59
770.24
809.73
927.11
Other Income
26.54
37.63
39.19
20.22
31.49
17.79
28.74
36.49
73.53
Total Income
841.18
936.2
728.49
597.43
778.95
769.37
798.98
846.22
1,000.64
Expenses
651.7
740.93
579.37
470.56
702.71
634.27
648.82
683.04
765.56
Operating Profit
162.94
157.64
109.94
106.65
44.74
117.32
121.42
126.69
161.55
Operating Profit Margin %
20%
17.54%
15.95%
18.48%
5.99%
15.61%
15.76%
15.65%
17.43%
Profit Before Interest, Tax and Depreciation
189.48
195.27
149.12
126.87
76.24
135.11
150.16
163.18
235.08
Interest
22.8
4.41
7.57
5.51
4.74
10.36
6.91
8.12
12.01
Depreciation
21.38
8.94
12.59
17.23
17.33
18.67
26.38
29.42
33.48
Profit Before Tax
145.3
181.92
128.96
104.13
54.17
106.08
116.87
125.64
189.59
Tax Paid
56.63
55.25
33.72
30.15
31.04
29.33
35.29
35.39
54.86
Profit After Tax
88.67
126.66
95.25
73.97
23.13
76.73
81.58
90.26
134.73
Total Net profit including share of profit / Loss from associate company
88.67
126.66
95.25
73.97
23.13
76.73
81.58
90.26
134.73
EPS
5.7
11.99
9.43
6.64
1.46
6.83
7.23
8.02
12.23
Actual EPS
5.7
11.99
9.43
6.64
1.46
6.83
7.23
8.02
12.23
Adjusted EPS
5.7
11.99
9.43
6.64
1.46
6.83
7.23
8.02
12.23
Diluted EPS
5.7
11.99
9.43
6.49
1.43
6.72
7.11
7.95
12

Bliss GVS Pharma Ltd Cash Flow

Figures in Rupees Crores

Mar 2016
Mar 2017
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
Net Cash from Operating Activities
112.95
289.47
17.64
39.95
46.7
63.97
135.48
34.31
102.82
105.91
138.72
Cash Flow from Investing Activities
-51.55
-249.23
47.87
-78.7
-40.09
-45.37
-102.89
-6.36
-83.34
-75.49
-38.17
Cash Flow from Financing Activities
-40.25
-10.13
-75.98
16.83
-6.3
-20.79
-23.73
-24.95
-20.88
-30.2
-89.21
Net Cash Flow
22.51
30.11
-10.46
-21.91
0.3
-2.21
8.85
3.02
-1.42
0.23
11.32

Bliss GVS Pharma Stock Shareholding Pattern

Numbers in percentages

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Promoters
34.97%
34.97%
34.9%
34.82%
35.1%
35.29%
35.44%
35.39%
35.36%
35.36%
35.01%
DII
6.59%
6.59%
6.58%
6.57%
6.55%
6.55%
6.54%
5.98%
5.78%
5.04%
9.47%
FII
0%
14.73%
13.25%
12.13%
13.51%
13.18%
12.65%
13.27%
14.54%
10.45%
8.07%
Public
43.08%
43.71%
45.27%
46.49%
44.84%
44.98%
45.36%
45.36%
44.32%
49.15%
47.45%
Total Outstanding Shares
10,46,90,822
10,46,90,822
10,48,82,572
10,51,44,472
10,53,66,272
10,53,70,272
10,54,97,522
10,56,49,472
10,57,88,972
10,57,88,972
10,60,56,222
Total Shareholders
40,758
45,157
44,737
52,937
49,558
49,517
46,707
44,461
43,380
44,874
46,767

Mutual Funds Buying / Exiting Bliss GVS Pharma

Holdings as of 15 Sep 2026 · based on the latest SEBI-mandated portfolio disclosures

Mutual Funds Buying Bliss GVS Pharma

Sorted by largest increase in holding, month-over-month.

Fund Name

Value of Holding

Increase (MoM)

Holding %

Bandhan BSE Healthcare Index Fund Direct Growth

Bandhan BSE Healthcare Index Fund Direct Growth

₹0.06 Cr

₹0.00 Cr (+5.77%)

0.19%

Mutual Funds Exiting Bliss GVS Pharma

Sorted by largest decrease in holding, month-over-month.

Fund Name

Value of Holding

Decrease (MoM)

Holding %

Union Active Momentum Fund Direct Growth

Union Active Momentum Fund Direct Growth

₹15.68 Cr

₹1.83 Cr (-10.45%)

2.22%

Bliss GVS Pharma Corporate Actions

View detailed summary of the earnings and dividend history of Bliss GVS Pharma.

  • Bliss GVS Pharma Ltd Earnings Results

    Bliss GVS Pharma Ltd’s net profit jumped 16.4% since last year same period to ₹50.10Cr in the Q1 2026-2027. On a quarterly growth basis, Bliss GVS Pharma Ltd has generated 40.81% jump in its net profits since last 3-months.

    Read More about Earnings Results

  • Bliss GVS Pharma Ltd Dividends May,2026

    In the quarter ending March 2026, Bliss GVS Pharma Ltd has declared dividend of ₹1.00 per share on 12 May 2026 - translating a dividend yield of 0.21%.

    Read More about Dividends

Indices Featuring Bliss GVS Pharma Stock

Check stock indices that include Bliss GVS Pharma.

BSE Healthcare

₹50,364.69

-114.12 (▲0.23%)

Insights on Bliss GVS Pharma Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, BLISSGVS has outperformed top 5 stocks with highest market-cap in Pharmaceuticals

  • imgPOSITIVE IMPACT

    MF Holding Up

    img

    Mutual Funds have increased holdings from 0.00% to 0.26% in Jun 2026 quarter

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 3 quarters, 23.27 Cr → 50.1 Cr (in ₹), with an average increase of 31.8% per quarter

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 3 quarters, 236.71 Cr → 295.18 Cr (in ₹), with an average increase of 10.4% per quarter

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, BLISSGVS has outperformed top 5 stocks with highest market-cap in Pharmaceuticals

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 6 months, BLISSGVS stock has moved up by 238.8%

  • imgNEGATIVE IMPACT

    Retail Holding Down

    img

    Retail Investor have decreased holdings from 49.15% to 47.45% in Jun 2026 quarter

  • imgNEGATIVE IMPACT

    FII Holding Down

    img

    Foreign Institutions have decreased holdings from 10.45% to 8.07% in Jun 2026 quarter

  • imgNEGATIVE IMPACT

    Promoter Holding Down

    img

    Promoters have decreased holdings from 35.36% to 35.01% in Jun 2026 quarter

About Bliss GVS Pharma Ltd

Bliss GVS Pharma Ltd is an export-oriented pharmaceutical company providing products in the antimalarial, antifungal, antibacterial, anti-inflammatory, and antibiotic segments. Boasting one of the largest portfolios of Suppositories and Pessaries dosage forms, the leading company is the only EUGMP certified suppositories manufacturer in India, and has a research and development centre with over 50 scientists certified by the Department of Scientific and Industrial Research.

Bliss GVS Pharma has a successful history, with various achievements over the years, such as investment in 51 share capital of Lifeon Labs Pvt Ltd. and the formation of a new company, Asterisk Lifesciences Limited, as a wholly owned foreign subsidiary in the UK for registrations and marketing in Europe. The company has also procured a USD 111.40 million contract from Aon.

To further its growth, Bliss GVS Pharma divested three subsidiaries and one stepdown subsidiary in 2018. The company also invested in a new 200,000 sq. ft. multiproduct facility in Maharashtra, equipped with state-of-the-art process equipment and utilities. In the financial year 2019-2020, the company had 4 wholly owned subsidiaries and 3 stepdown subsidiaries.

Revenue: ₹285.58Cr as on June 2026 (Q1 FY27)
Net Profit: ₹51.37Cr as on June 2026 (Q1 FY27)
Listing date: 26 Jul, 2010
Chairperson Name: Subramanian R Vaidya
OrganisationBliss GVS Pharma Ltd
HeadquartersMumbai
IndustryPharmaceuticals
CEOSubramanian R Vaidya
E-voting on sharesClick here to vote

FAQs

What is Bliss GVS Pharma share price today?

Bliss GVS Pharma share price today stands at ₹666 as on . Bliss GVS Pharma share today touched a day high of ₹676.45 and a low of ₹650.75.

What is the 52 week high and 52 week low range for Bliss GVS Pharma share?

Bliss GVS Pharma touched a 52 week high of ₹725.9 and a 52 week low of ₹118. Bliss GVS Pharma share price today i.e. is trending at ₹666, which is -8.25% down from its 52 week high and 464.41% up from its 52 week low.

What is Bliss GVS Pharma's market capitalisation today?

Bliss GVS Pharma market capitalisation is ₹7,283.11 Cr as on .

How to buy Bliss GVS Pharma shares?

To buy Bliss GVS Pharma shares, you need to follow these steps:

  • Open a Demat account and Trading account on INDmoney
  • Fund your Trading account
  • Search for BLISSGVS or Bliss GVS Pharma Ltd on the INDmoney app to check live prices of the stock
  • Click on Buy or SIP to place an order to invest in Bliss GVS Pharma shares. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.

What is Bliss GVS Pharma trading volume today?

Bliss GVS Pharma trading volume is 3.39L as on . This means that 3.39L shares of Bliss GVS Pharma were bought and sold on the stock market during today's trading session.

What are INDmoney investors doing with Bliss GVS Pharma shares right now?

Based on aggregated, anonymised INDmoney platform data, search interest and investment activity in Bliss GVS Pharma have both increased over the past 30 days, and the average INDmoney investor holds the stock for 11 days. This reflects platform activity only and is not investment advice.